Altered expression of ß-tubuin isotypes in breast cancer cells resistant to docetaxel

Kawan Shalli, Iain Brown, Steven Darryll Heys, Andrew Craig Schofield

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin isotypes in vitro and has sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel. Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to docetaxel in vitro. Expression of beta-tubulin isotypes ( class I, II, III, IVa, IVb, and VI) was determined at the RNA and protein level using RT-PCR and western analysis, respectively. DNA sequencing evaluated the beta-tubulin gene. At the mRNA level, class I, II, III, and IVa beta-tubulin mRNA isotypes were over-expressed in docetaxel-resistant MCF-7 cells when compared with the docetaxel-sensitive parental cells. However, class VI beta-tubulin mRNA isotype expression was decreased in resistant cells. In MDA-MB-231 cells, there was a decrease in expression of the class I and class IVa beta-tubulin mRNA. However, there were increased expressions in class II, IVb, and VI beta-tubulin mRNA isotypes in resistant cells. Western analysis has confirmed corresponding increases in beta-tubulin protein levels in MCF- 7 cells. However, in MDA-MB-231 cells, there were decreased protein levels for class II and class III beta-tubulin. This study demonstrates that altered expression of mRNA beta-tubulin isotypes and modulation of beta-tubulin protein levels are associated with acquired docetaxel resistance in breast cancer cells. This allows further understanding and elucidation of mechanisms involved in resistance to docetaxel.

Original languageEnglish
Pages (from-to)1299-1301
Number of pages2
JournalThe FASEB Journal
Volume19
DOIs
Publication statusPublished - Aug 2005

Keywords

  • drug resistance
  • MCF-7 and MDA-MB-231 cells
  • EXPRESSION
  • CHEMOTHERAPY
  • TAXOL
  • MICROTUBULES
  • PREDICTION
  • MUTATIONS
  • CARCINOMA
  • DYNAMICS
  • TAXOTERE

Cite this

Altered expression of ß-tubuin isotypes in breast cancer cells resistant to docetaxel. / Shalli, Kawan; Brown, Iain; Heys, Steven Darryll; Schofield, Andrew Craig.

In: The FASEB Journal, Vol. 19, 08.2005, p. 1299-1301.

Research output: Contribution to journalArticle

Shalli, Kawan ; Brown, Iain ; Heys, Steven Darryll ; Schofield, Andrew Craig. / Altered expression of ß-tubuin isotypes in breast cancer cells resistant to docetaxel. In: The FASEB Journal. 2005 ; Vol. 19. pp. 1299-1301.
@article{0c5444ffc4724a16982e63018dfdb109,
title = "Altered expression of {\ss}-tubuin isotypes in breast cancer cells resistant to docetaxel",
abstract = "Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin isotypes in vitro and has sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel. Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to docetaxel in vitro. Expression of beta-tubulin isotypes ( class I, II, III, IVa, IVb, and VI) was determined at the RNA and protein level using RT-PCR and western analysis, respectively. DNA sequencing evaluated the beta-tubulin gene. At the mRNA level, class I, II, III, and IVa beta-tubulin mRNA isotypes were over-expressed in docetaxel-resistant MCF-7 cells when compared with the docetaxel-sensitive parental cells. However, class VI beta-tubulin mRNA isotype expression was decreased in resistant cells. In MDA-MB-231 cells, there was a decrease in expression of the class I and class IVa beta-tubulin mRNA. However, there were increased expressions in class II, IVb, and VI beta-tubulin mRNA isotypes in resistant cells. Western analysis has confirmed corresponding increases in beta-tubulin protein levels in MCF- 7 cells. However, in MDA-MB-231 cells, there were decreased protein levels for class II and class III beta-tubulin. This study demonstrates that altered expression of mRNA beta-tubulin isotypes and modulation of beta-tubulin protein levels are associated with acquired docetaxel resistance in breast cancer cells. This allows further understanding and elucidation of mechanisms involved in resistance to docetaxel.",
keywords = "drug resistance, MCF-7 and MDA-MB-231 cells, EXPRESSION, CHEMOTHERAPY, TAXOL, MICROTUBULES, PREDICTION, MUTATIONS, CARCINOMA, DYNAMICS, TAXOTERE",
author = "Kawan Shalli and Iain Brown and Heys, {Steven Darryll} and Schofield, {Andrew Craig}",
year = "2005",
month = "8",
doi = "10.1096/FJ.04-3178FJE",
language = "English",
volume = "19",
pages = "1299--1301",
journal = "The FASEB Journal",
issn = "0892-6638",
publisher = "FEDERATION AMER SOC EXP BIOL",

}

TY - JOUR

T1 - Altered expression of ß-tubuin isotypes in breast cancer cells resistant to docetaxel

AU - Shalli, Kawan

AU - Brown, Iain

AU - Heys, Steven Darryll

AU - Schofield, Andrew Craig

PY - 2005/8

Y1 - 2005/8

N2 - Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin isotypes in vitro and has sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel. Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to docetaxel in vitro. Expression of beta-tubulin isotypes ( class I, II, III, IVa, IVb, and VI) was determined at the RNA and protein level using RT-PCR and western analysis, respectively. DNA sequencing evaluated the beta-tubulin gene. At the mRNA level, class I, II, III, and IVa beta-tubulin mRNA isotypes were over-expressed in docetaxel-resistant MCF-7 cells when compared with the docetaxel-sensitive parental cells. However, class VI beta-tubulin mRNA isotype expression was decreased in resistant cells. In MDA-MB-231 cells, there was a decrease in expression of the class I and class IVa beta-tubulin mRNA. However, there were increased expressions in class II, IVb, and VI beta-tubulin mRNA isotypes in resistant cells. Western analysis has confirmed corresponding increases in beta-tubulin protein levels in MCF- 7 cells. However, in MDA-MB-231 cells, there were decreased protein levels for class II and class III beta-tubulin. This study demonstrates that altered expression of mRNA beta-tubulin isotypes and modulation of beta-tubulin protein levels are associated with acquired docetaxel resistance in breast cancer cells. This allows further understanding and elucidation of mechanisms involved in resistance to docetaxel.

AB - Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin isotypes in vitro and has sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel. Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to docetaxel in vitro. Expression of beta-tubulin isotypes ( class I, II, III, IVa, IVb, and VI) was determined at the RNA and protein level using RT-PCR and western analysis, respectively. DNA sequencing evaluated the beta-tubulin gene. At the mRNA level, class I, II, III, and IVa beta-tubulin mRNA isotypes were over-expressed in docetaxel-resistant MCF-7 cells when compared with the docetaxel-sensitive parental cells. However, class VI beta-tubulin mRNA isotype expression was decreased in resistant cells. In MDA-MB-231 cells, there was a decrease in expression of the class I and class IVa beta-tubulin mRNA. However, there were increased expressions in class II, IVb, and VI beta-tubulin mRNA isotypes in resistant cells. Western analysis has confirmed corresponding increases in beta-tubulin protein levels in MCF- 7 cells. However, in MDA-MB-231 cells, there were decreased protein levels for class II and class III beta-tubulin. This study demonstrates that altered expression of mRNA beta-tubulin isotypes and modulation of beta-tubulin protein levels are associated with acquired docetaxel resistance in breast cancer cells. This allows further understanding and elucidation of mechanisms involved in resistance to docetaxel.

KW - drug resistance

KW - MCF-7 and MDA-MB-231 cells

KW - EXPRESSION

KW - CHEMOTHERAPY

KW - TAXOL

KW - MICROTUBULES

KW - PREDICTION

KW - MUTATIONS

KW - CARCINOMA

KW - DYNAMICS

KW - TAXOTERE

U2 - 10.1096/FJ.04-3178FJE

DO - 10.1096/FJ.04-3178FJE

M3 - Article

VL - 19

SP - 1299

EP - 1301

JO - The FASEB Journal

JF - The FASEB Journal

SN - 0892-6638

ER -